China Extended eCTD Submission to Chemical Drugs and Biologics From 1 March 2026

On 15 January 2026 the National Medical Products Administration (NMPA) listed on its website its Announcement on the Full Implementation of eCTD Submission for Chemical Drugs and Biological Products, numbered Announcement No. 8 of 2026. A version reproduced on the Hunan provincial government portal shows the announcement dated 14 January 2026. Some reproductions give a shorter title without the words for full implementation, and the NMPA text should be treated as authoritative.

According to the announcement as reproduced, from 1 March 2026 applications for chemical drugs, chemical active pharmaceutical ingredients and biological products may be submitted in eCTD format. The application types listed are clinical trial applications, marketing authorisation applications, supplementary applications, re-registration applications for drugs manufactured outside China, and applications for generic drug quality and efficacy consistency evaluation.

The revised eCTD technical documents are issued separately by NMPA’s Center for Drug Evaluation (CDE). The eCTD Technical Specification V1.0 and related documents issued with Announcement No. 119 of 2021 were repealed with effect from 1 March 2026. Trade reports state that CDE released version 1.1.0 of the eCTD validation software with an operating manual, that version 1.0 is no longer applicable, and that the updated technical specification is version 1.1 based on ICH eCTD v3.2.2. These technical details were not confirmed in a CDE document seen for this brief.

The announcement includes a time-limited incentive. For one year from 1 March 2026, marketing authorisation applications submitted in eCTD format are included in NMPA’s priority acceptance service. They are queued separately, and the acceptance review stage is to be completed within three days.

This incentive applies to the acceptance step, which checks that an application is complete and in the right form before technical review begins. It does not shorten the scientific review. For sponsors planning a Chinese marketing application in the year to 28 February 2027, however, it offers a clear administrative reason to choose eCTD over the traditional format.

China introduced eCTD through Announcement No. 119 of 2021, which set out the original framework and the V1.0 technical specification. NMPA then widened the scope through Announcement No. 10 of 2025. According to consultancy reports, from 27 January 2025 eCTD could be used for clinical trial applications for chemical drugs in classes 1 to 5, marketing applications for chemical drugs in classes 2, 3, 4 and 5.2, and certain biological products, with applicants encouraged to transmit eCTD dossiers online. NMPA’s English website published a notice on that expansion dated 11 June 2025.

The 2026 announcement extends this to the main application types across chemical drugs, chemical APIs and biological products, and replaces the 2021 technical documents. Its wording is permissive: applications may use eCTD. The sources reviewed did not identify a date from which eCTD becomes the only accepted format, and secondary sources give conflicting descriptions of whether electronic submission is optional or mandatory. Sponsors should therefore read the announcement as a broad availability of eCTD with incentives, rather than as an immediate requirement, unless and until NMPA states otherwise.

Sponsors filing in China should first confirm that their publishing tools and service providers support the revised Chinese regional specification and the current CDE validation software. Dossiers prepared under the 2021 V1.0 specification will not meet the revised requirements, so templates and Module 1 content built for earlier Chinese eCTD submissions need to be reviewed.

Sponsors should also decide, for each planned application, whether to use eCTD now. For marketing applications in the year from 1 March 2026, the priority acceptance arrangement weighs in favour of eCTD. For products with global dossiers already in eCTD v3.2.2, the Chinese specification’s basis in v3.2.2, as reported by trade sources, reduces the conversion effort, although Chinese regional content and Module 1 requirements still apply.

Overseas sponsors are directly affected, because re-registration applications for drugs manufactured outside China are among the listed application types. Companies holding Chinese registrations for imported products should therefore consider the eCTD route for their next re-registration, as well as for new clinical trial and marketing applications. Regulatory teams that coordinate global filings may also wish to record China alongside Japan, the United States and the European Union in their eCTD planning, since each authority is now at a different stage: China on a specification reported to be based on v3.2.2, Japan requiring v4.0 for new applications, and the US and the EU accepting v4.0 on an optional basis.